Organogenesis Holdings INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Organogenesis Holdings Inc. reports a 31% increase in Q3 2025 net product revenue, driven by new products, but its second Phase 3 ReNu trial for knee OA did not achieve statistical significance for its primary endpoint.
NASDAQ
Organogenesis Holdings Inc. reported a significant decline in Q2 2025 revenue and a widened net loss, primarily driven by regulatory ambiguity in the advanced wound care market.
NASDAQ
10-Q: Organogenesis Holdings Inc. Reports Q1 2025 Results: Revenue Declines Amid LCD Implementation Delay
Organogenesis Holdings Inc. experienced a 21% decrease in net revenue for the first quarter of 2025, primarily due to the delayed implementation of local coverage determinations (LCDs) and subsequent customer behavior changes.
NASDAQ
10-Q: Organogenesis Holdings Reports Q3 2024 Results, Secures $130 Million in Preferred Stock Financing
Organogenesis Holdings announced its third-quarter 2024 financial results, highlighted by a 6% increase in net revenue and a significant $130 million investment through a preferred stock offering.
NASDAQ
10-Q: Organogenesis Holdings Reports Mixed Q2 Results Amidst Strategic Shifts and Regulatory Uncertainty
Organogenesis Holdings Inc. reported a net loss for the second quarter of 2024, alongside revenue growth and strategic adjustments, including an impairment charge and a software write-down.
NASDAQ
Organogenesis Holdings Inc. reports a modest revenue increase in Q1 2024, alongside a net loss, while managing costs and navigating regulatory challenges.